7 Reasons Biomedical Companies Choose Northern Kentucky

Biomedical companies, whether clinical research organizations, diagnostics manufacturers, pharmaceutical developers, or biomedical startups, make location decisions on a specific set of criteria: proximity to academic medical centers, access to wet lab space, a clinical trial patient population, a specialized workforce, and a cost structure that preserves capital for R&D. Northern Kentucky delivers on all five. And in 2025 and 2026, the region made two investments that transformed its biomedical infrastructure from promising to purpose-built.

In December2025, LifeSciKY, the region’s first fully equipped biomedical wet lab incubator, opened its doors inside the new OneNKY Center in Covington. In June 2026, the $125 million Commonwealth Center for Biomedical Excellence broke ground on Covington’s riverfront, a 120,000 sq. ft. facility that will co-locate the University of Kentucky College of Medicine’s Northern Kentucky campus with NKU’s Chase College of Law, blocks from the region’s biomedical company cluster. Together, these two investments represent the most significant expansion of biomedical infrastructure in Northern Kentucky’s history.

The seven reasons below explain why biomedical companies keep choosing this region, each grounded in recent investment decisions and verifiable data.

Northern Kentucky Biomedical: By the Numbers

1. The Region Just Got a Purpose-Built Biomedical Ecosystem, Two New Facilities, One Cluster

For years, the knock on Northern Kentucky’s biomedical sector was that the companies were here, but the specialized infrastructure wasn’t. That has now changed decisively, with two major investments that create a purpose-built biomedical campus in downtown Covington.

LifeSciKY at the OneNKY Center, open December 2025. The LifeSciKY lab inside the OneNKY Center is the only fully equipped biomedical wet lab incubator in the Cincinnati region, providing biomedical startups and early-stage companies access to BSL-2-ready lab space, shared instrumentation, and a support ecosystem without the capital cost of building their own facility. Per the Kentucky Cabinet for Economic Development’s March 2026 announcement, LifeSciKY Executive Director Christin Godale described the value for new entrants directly: “Access to a fully equipped lab, without the time and expense of building one, means experiments start faster, data comes sooner, and capital lasts longer.” In March 2026, Mitsui Chemicals America became LifeSciKY’s first major international partner, locating its InnoCell platform in the lab to develop next-generation cell culture materials, confirming that the facility is already attracting global life science companies.

Commonwealth Center for Biomedical Excellence, groundbreaking June 2026. The $125 million Commonwealth Center for Biomedical Excellence broke ground on June 11, 2026, at 11 East Rivercenter Blvd. in Covington, a 120,000 sq. ft. facility that will house the University of Kentucky College of Medicine’s Northern Kentucky Campus and NKU’s Salmon P. Chase College of Law on a 1.89-acre riverfront site, per the NKY Port Authority’s project page. Crucially, the center is sited within walking distance of LifeSciKY, CTI Clinical Trial and Consulting Services, Bexion Pharmaceuticals, and Gravity Diagnostics, placing medical students directly inside the existing biomedical company cluster from day one. The $125 million was secured through the Kentucky General Assembly in 2024 by Senate Budget Chair Chris McDaniel, per Kenton County.Construction is expected to be completed by the end of 2028.

Together, these two facilities represent a structural upgrade to NKY’s biomedical positioning that no competitor market in the Midwest can match on this timeline. A biomedical company locating in Covington today can access wet lab space immediately, with a future-state medical school campus completing next door in 2028.

2. Thermo Fisher Has Invested $106 Million Here, and Keeps Coming Back

The most powerful proof point for any company evaluating a biomedical location is what the world’s leading companies in the sector have already decided. In Northern Kentucky’s case, Thermo Fisher Scientific, the world leader in serving science, has chosen NKY twice, with two  major expansions separated by two years.

In October 2022, the Kentucky Cabinet for Economic Development announced Thermo Fisher’s PPD clinical research business would invest $59 million and create 200+ jobs, expanding its facility in Campbell County’s Highland Heights, a long-term commitment from a company that has operated in Kentucky since 2002. Then in June 2024, the Cabinet announced a second expansion: $47.8 million and 250+ new jobs, with Thermo Fisher nearly doubling its laboratory footprint by opening a new 65,000 sq. ft. sample management and biorepository facility in Covington, chosen specifically because of its proximity to LifeSciKY and the growing Covington biomedical cluster.

Combined, Thermo Fisher has invested over $106 million in Northern Kentucky across these two rounds, creating 450+ jobs in clinical research services that support pharmaceutical and biotech customers running trials in more than 100 countries. Per the NKY Tribune’s coverage, Kenton County Judge/Executive Kris Knochelmann noted: “With the [LifeSkiKY] being located in Covington amidst a cluster of life sciences companies, Kenton County is a natural location for an expansion of PPD.”

3. A Biomedical Company Cluster Already Operating at Meaningful Scale

Northern Kentucky is not asking biomedical companies to pioneer a new market; it is inviting them into a cluster of established companies that have already built reputations, client bases, and partnerships in the region.

Gravity Diagnostics

A CAP-accredited, CLIA-certified laboratory headquartered in Covington, Gravity Diagnostics was one of the nation’s early leaders in COVID-19 testing protocol development. Today the company focuses on diagnostics spanning toxicology, pharmacogenetics, infectious and respiratory disease, and blood analysis, serving healthcare providers across the region and nationally.

CTI Clinical Trial and Consulting Services

Ranked as the #1 CRO in sponsor satisfaction, CTI has touched more than 10,000 projects since its founding in 1999, supporting drug and device approvals for diseases including sickle cell disease, macular degeneration, uterine fibroids, and asthma. CTI operates in Covington and is one of the anchor companies in the emerging Covington biomedical cluster, directly adjacent to the future Commonwealth Center for Biomedical Excellence site.

Bexion Pharmaceuticals

Bexion is a mid-stage clinical company based in Covington developing life-changing treatments in oncology and central nervous system disease. In 2024, Bexion announced a new phase of a novel cancer treatment, and is among the companies that have benefited directly from Kentucky’s SBIR-STTR match program, which multiplies federal R&D funding for innovative companies in the state, per BE NKY.

Wood Hudson Cancer Research Laboratory

Located in Newport, Wood Hudson holds more than 2 million human tissue cancer and non-cancer specimens used across multiple research programs, including research into the environmental causes of cancer. It is the only research center of its kind in Kentucky, per BE NKY.

Andritz Separation

A global leader in chemical separation systems, Andritz operates in NKY, providing solutions for active pharmaceutical ingredients (APIs), vitamins, and antibiotics, serving the pharmaceutical and biomedical manufacturing supply chain across the region.

Gen9

Gen9 is developing AI-driven wearable technology, including smartwatches and connected eyewear, to support aging populations with grants from the National Institutes of Health and the National Institute on Aging. Their NKY operations put them within the same innovation corridor as the region’s clinical research organizations and academic medical partners.

“Every company that chooses LifeSciKY strengthens our innovation ecosystem, creates high-quality jobs and helps position Kentucky as a competitive, global hub for life sciences.”

— Christin Godale, Executive Director, LifeSciKY, as quoted in the Kentucky Cabinet for Economic Development’s March 2026 announcement

4. Kentucky’s Incentive Programs Are Specifically Designed for Biomedical R&D Companies

Biomedical companies, particularly early-stage companies where capital efficiency is existential, benefit from Kentucky’s suite of incentives that directly address the economics of research, development, and clinical operations.

• The Kentucky SBIR-STTR Match Program matches federal Small Business Innovation Research and Small Business Technology Transfer funds, effectively doubling the R&D capital available to qualifying biomedical companies. Bexion Pharmaceuticals has used this program directly, per BE NKY.
• The Kentucky Enterprise Initiative Act (KEIA) refunds sales and use taxes on equipment purchases and property improvements, directly applicable to laboratory instrumentation, biorepository equipment, and facility build-out.
• The Kentucky Business Investment (KBI) Program provides tax credits and wage incentives tied to job creation, the primary incentive structure used by Thermo Fisher in both its 2022 and 2024 NKY expansions, per the Kentucky Cabinet for Economic Development.
• The Bluegrass State Skills Corporation Skills Training Investment Credit offsets the cost of training clinical research, lab technician, and biomedical manufacturing employees.
• The Kentucky Enterprise Fund provides capital for early-stage companies commercializing a technology-based product or process, directly applicable to biomedical startups moving from research to production, per BE NKY’s life science overview.
• Commonwealth Seed Capital, LLC makes equity investments in early-stage Kentucky companies with significant in-state presence, a funding mechanism available to biomedical startups operating out of LifeSciKY’s incubator.

BE NKY Growth Partnership provides no-cost assistance navigating every available incentive for biomedical companies evaluating Northern Kentucky.

5. A Research and Talent Pipeline Built for the Next Generation of Biomedical Science

Biomedical companies need a specific kind of talent: researchers trained in laboratory science, clinical trial protocols, diagnostic imaging, biomedical engineering, and data analysis. Northern Kentucky has built that pipeline through a combination of university partnerships, research programs, and co-op arrangements with regional biomedical employers.

Within a 75-mile radius of Northern Kentucky, there are 25+ four-year colleges and universities, per BE NKY’s biomedical research page. Three of those colleges alone invested more than $100 million in life sciences R&D over a five-year period. The University of Cincinnati’s Biomedical Engineering program places students in co-op rotations directly with regional biomedical companies, including at Cincinnati Children’s Hospital Medical Center. The University of Kentucky College of Medicine’s Northern Kentucky Campus trains physicians within St. Elizabeth Healthcare’s system, producing clinically trained graduates who understand both the science and the regional patient population.

The University of Cincinnati Medical School, the second oldest college of medicine in the United States, remains a national leader in biomedical research, with its research enterprise generating discoveries that flow into the regional commercialization ecosystem. And once the Commonwealth Center for Biomedical Excellence opens, UK College of Medicine students will complete their training blocks from CTI, Bexion, and Gravity Diagnostics, creating a direct pipeline from medical education to biomedical employment that few Midwest markets can replicate.

6. A Location That Serves Clinical Trials and Patient Recruitment

For clinical research organizations and pharmaceutical companies running trials, the quality of a location depends heavily on access to a large, diverse patient population. Northern Kentucky’s position at the center of the Cincinnati metropolitan area, a region of 2.3 million people with a major academic medical center, a large community hospital system (St. Elizabeth Healthcare), and a population that spans urban, suburban, and rural demographics, makes it an effective trial recruitment market.

Per BE NKY’s supply chain overview, 54% of the U.S. population lives within a one-day drive of Northern Kentucky, which for clinical trial coordinators means trial participants, site investigators, and sponsor representatives can all access the region efficiently. CTI Clinical Trial and Consulting Services has leveraged this position for 25+ years, conducting trials that have supported more than 150 drug and device approvals. Thermo Fisher’s PPD business specifically cited the regional patient access environment when selecting its Covington expansion site, per the Kentucky Cabinet for Economic Development.

7. Infrastructure and Operating Cost Advantages That Preserve R&D Capital

Biomedical companies, especially pre-revenue startups and early-stage clinical companies, need every dollar they can find for R&D. Northern Kentucky’s operating cost structure provides meaningful advantages that compound over time.

Industrial electricity costs run 11% below the national average, a significant advantage for laboratories and biorepositories that operate equipment around the clock. According to BE NKY’s infrastructure overview, the region’s fiber optic network is among the most extensive in the country, critical for biomedical companies transferring large clinical data sets, genomic sequencing files, and imaging data between sites. And lab and office space in Covington’s riverfront district, where the biomedical cluster is concentrating, is significantly more affordable than comparable space in Boston, San Diego, or Research Triangle Park.

For startups specifically, LifeSciKY‘s incubator model eliminates the single largest capital barrier in early-stage biomedical company formation: building or outfitting a laboratory. Per the Kentucky Cabinet for Economic Development, LifeSciKY’s model is designed so that companies can begin experiments within days of joining the program, compressing the timeline from funding to data generation that is often the most capital-intensive phase of early biomedical development.

• Thermo Fisher Scientific / PPD: $59M, 200+ jobs (2022), Campbell County expansion, clinical research lab. Per Kentucky Cabinet for Economic Development.
• Thermo Fisher Scientific / PPD: $47.8M, 250+ jobs (2024), Covington expansion, 65,000 sq ft biorepository and sample management facility. Per Kentucky Cabinet for Economic Development.
• LifeSciKY at OneNKY Center: $15M state investment, opened December2025, Only fully equipped biomedical wet lab incubator in the Cincinnati region. Per Kentucky Cabinet for Economic Development.
• Mitsui Chemicals America / InnoCell: new partnership, March 2026, First international company to locate R&D operations at LifeSciKY, developing cell culture materials at OneNKY Center. Per Kentucky Cabinet for Economic Development.
• Commonwealth Center for Biomedical Excellence: $125M, groundbreaking June 2026, 120,000 sq ft, UK College of Medicine + NKU Chase Law, Covington riverfront. Per NKY Port Authority.
• Bexion Pharmaceuticals: active Phase 2 oncology trials (2024–ongoing), Covington-based, supported by Kentucky SBIR-STTR match. Per BE NKY.

Ready to Explore Northern Kentucky for Your Biomedical Company?

BE NKY Growth Partnership provides no-cost site selection support for biomedical research companies, CROs, diagnostics manufacturers, and life science startups evaluating the region. Their team can connect you with available lab space at LifeSciKY, identify the right combination of SBIR-STTR match, KBI, and KEIA incentives for your stage of development, and introduce you to the clinical research and academic medical center partnerships that make NKY’s biomedical ecosystem work.

Since 2019, BE NKY has driven 130 project wins, creating 10,570 jobs and $2 billion in capital investment, with life sciences delivering a 21.5% projected employment growth rate as one of the region’s fastest-growing sectors, per BE NKY’s impact report. Contact BE NKY today to start the conversation.